Vergelijking
AOD-9604 vs. CJC-1295
Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.
Identiteit
Categorie
Groei
Groei
CAS-nr.
221231-10-3
geen gegevens
Molecuulmassa
1815.09 g/mol
3647.3 g/mol
Halfwaardetijd
0.4 h
144 h
Sequentie
Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-PheYADAIFTNSYRKVLGQLSARKLLQDIMSR-DACWerkingsmechanisme
AOD-9604
AOD-9604 corresponds to the C-terminal fragment 176-191 of human growth hormone with an additional N-terminal tyrosine. In animal models, lipolytic effects without GH-typical adverse events (insulin resistance, IGF-1 rise) were reported. In humans, these preclinical findings did not translate into clinically relevant weight reduction in the four phase-2 obesity trials. The exact human mechanism of action is unclear; the GH receptor is not classically activated by the fragment.
CJC-1295
Synthetic analogue of growth-hormone-releasing hormone (GHRH), modified for extended half-life via a Drug Affinity Complex (DAC) binding to albumin. Acts on the pituitary GHRH receptor and stimulates endogenous growth-hormone release.
Bewijsbasis
Hoogste bewijs
Humane RCT
Humane studie
Studies
3
4
waarvan bij mensen
2
3
Geregistreerde effecten
3
3
Openstaande tegenstrijdigheden
1
1
Gedocumenteerde bijwerkingen
1
3
Juridische status
Volledige vermeldingen
Frequently asked questions
- What is the difference between AOD-9604 and CJC-1295?
- AOD-9604 is classified as "Groei", while CJC-1295 is classified as "Groei". AOD-9604: Synthetic 16-amino-acid peptide corresponding to the C-terminal fragment of human growth hormone (hGH 176-191). Originally developed by Metabolic Pharmaceuticals as an oral obesity therapy; all phase-2 trials missed the primary endpoint. No marketing approval. The Australian TGA Schedule 4 classification is often misunderstood. CJC-1295: Long-acting synthetic GHRH analogue modified for albumin binding (DAC). Stimulates endogenous growth-hormone release. Pharmacodynamic effect established in small human studies; clinical endpoint trials are missing. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, AOD-9604 or CJC-1295?
- The highest available evidence level is "Humane RCT" for AOD-9604 and "Humane studie" for CJC-1295. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of AOD-9604 and CJC-1295 in Germany and the United States?
- Duitsland: AOD-9604 — Niet goedgekeurd, CJC-1295 — Niet goedgekeurd. Verenigde Staten: AOD-9604 — Niet goedgekeurd, CJC-1295 — Alleen onderzoek. These are factual summaries with source and review date on the individual pages.